Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at the 2021 San Antonio Breast Cancer Symposium
Oncolytics Biotech will present updates on the Phase 2 IRENE trial for treating metastatic triple-negative breast cancer (TNBC) at the 2021 San Antonio Breast Cancer Symposium from December 7-10, 2021. The study evaluates the combination of pelareorep and Incyte's anti-PD-1 inhibitor, retifanlimab, on 25 patients. This open-label trial focuses on safety and response rates, with secondary endpoints including progression-free survival and overall survival. The IRENE trial is crucial in advancing pelareorep as a potential treatment option in oncology.
- Presentation of Phase 2 IRENE trial signifies progress in cancer treatment research.
- Study evaluates a promising combination therapy for metastatic TNBC.
- None.
IRENE study is evaluating pelareorep-anti-PD-1 combination treatment in metastatic TNBC
SAN DIEGO and CALGARY, AB, Nov. 19, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will present an update on the Phase 2 IRENE trial in a poster at the 2021 San Antonio Breast Cancer Symposium (SABCS), which is taking place December 7 – 10, 2021, both virtually and in-person, at the Henry B. González Convention Center in San Antonio, Texas.
Details on the poster and its corresponding abstract, available on the SABCS website, are shown below.
Program Number: OT2-25-01
Title: IRENE study: Phase 2 study of INCMGA00012 and the oncolytic virus pelareorep in metastatic triple negative breast cancer
Session Name: Ongoing Trials Poster Session 2
Session Date: December 9, 2021
Session Time: 5:00 PM – 6:30 PM CT / 6:00 PM – 7:30 PM ET
Presenter: Dr. Mridula George
About IRENE
The IRENE (INCMGA00012 and the oncolytic virus pelareorep in metastatic triple-negative breast cancer) study is a single-arm, open-label, phase 2 study evaluating the combination of pelareorep and Incyte's anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012) for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer. The study will enroll 25 patients and is being conducted at the Rutgers Cancer Institute of New Jersey and The Ohio State University Comprehensive Cancer Center.
Study participants will receive pelareorep intravenously on days 1, 2, 15, and 16 of 28-day treatment cycles. Retifanlimab will be administered on day 3 of each cycle, with treatment cycles continuing until disease progression is observed. The co-primary endpoints of the study are safety and objective response rate. Secondary endpoints include progression-free survival, overall survival, and duration of response. Exploratory endpoints include peripheral T cell clonality and pre- vs. post-treatment change in tumor PD-L1 expression.
For more information on the IRENE study, refer to https://clinicaltrials.gov/ct2/show/NCT04445844.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Company Contact Jon Patton Director of IR & Communication +1-858-886-7813 | Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-917-679-9282 |
View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-present-phase-2-triple-negative-breast-cancer-trial-update-at-the-2021-san-antonio-breast-cancer-symposium-301428864.html
SOURCE Oncolytics Biotech® Inc.
FAQ
What is the IRENE trial for ONCY?
When will ONCY present the IRENE trial update?
What are the primary endpoints of the IRENE trial?
How many patients are enrolled in the IRENE trial?
What does the combination therapy in the IRENE trial involve?
